Firstly, in a mouse model of experimental nonalcoholic steatohepatitis, SB (20 mg/kg intraperitoneally for 4 weeks) was reported to affect lipid homeostasis and to supress NF-κB activation in the liver [90]. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.